About us
Biozep AS is a Norwegian company developing novel drugs for severe eye diseases which can lead to vision impairment and vision loss. Biozep focus on eye diseases with a high unmet medical need like noninfectious uveitis, age-related macular degeneration (AMD) and diabetic retinopathy (DR).
Our drug substances are based on a proprietary drug molecule platform called Therapeutic Active Lipids (TA-Lipids), and we have more than 20 years of experience in identifying and validating “druggable” targets for these TA-Lipids.
Biozep has discovered a group of TA-Lipids with a great potential in treatment of dry AMD and diabetic retinopathy because the lipids can protect retinal cells from oxidative stress damage and reduce chronic inflammation. These are processes known to be involved in the development of several diseases of the retina.
The company will during 2018 initiate proof of concept studies in animal models.
Our drug substances are based on a proprietary drug molecule platform called Therapeutic Active Lipids (TA-Lipids), and we have more than 20 years of experience in identifying and validating “druggable” targets for these TA-Lipids.
Biozep has discovered a group of TA-Lipids with a great potential in treatment of dry AMD and diabetic retinopathy because the lipids can protect retinal cells from oxidative stress damage and reduce chronic inflammation. These are processes known to be involved in the development of several diseases of the retina.
The company will during 2018 initiate proof of concept studies in animal models.
Partners
Biozep seek strategic partnership with pharmaceutical companies early in the drug development phase to speed up product development, extend our drug pipeline, reduce risk and reduce the need of private capital.
Business opportunity
Ophthalmic drugs are used to treat eye diseases such as uveitis, glaucoma, AMD, diabetic retinopathy, cataract and dry eye disease. According to a market report published by Transparency Market Research "Ophthalmic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2018" the global ophthalmic drugs market was valued at USD 16 billion in 2012 and is expected to grow at a CAGR of 5.2% from 2013 to 2018, to reach an estimated value of USD 21.6 billion in 2018. The increase in the aging population is one of the main reasons for the increased market.